On this page
# Healthcare and Pharma Unlisted Shares in India — What Investors Should Know
India's healthcare sector is one of the few that can credibly claim both defensive characteristics and strong growth. Rising insurance penetration, an expanding diagnostics sector, the transition from unorganised to organised care, and a growing digital health ecosystem make healthcare one of the most interesting sectors for long-term unlisted investors.
This article maps the unlisted healthcare landscape and what to evaluate before buying.
Disclaimer: Healthcare company valuations are complex and highly dependent on management quality, regulatory approvals, and contract timelines. This is educational content, not investment advice.
Why Healthcare is Structurally Attractive
1. Health Insurance Penetration India's health insurance penetration has been rising sharply, helped by government schemes (Ayushman Bharat) and private insurer expansion. More insurance means more utilisation — more tests ordered, more elective procedures booked, more prescriptions filled.
2. Shift from Unorganised to Organised India's healthcare market remains significantly unorganised. Local diagnostics labs, single-doctor clinics, and independent pharmacies are being displaced by organised chains with standardised quality, technology integration, and brand trust. This consolidation benefits organised players.
3. Chronic Disease Burden India has among the world's largest diabetic and hypertensive populations. Chronic disease management requires recurring tests, prescriptions, and monitoring — creating a high-frequency, recurring revenue model for healthcare providers.
4. Digital Health Momentum Telemedicine, app-based health records, home diagnostics, and wearables are growing rapidly. Several digital health companies raised large rounds and are pre-IPO.
Sub-sectors in the Unlisted Healthcare Market
### Diagnostics Chains Regional diagnostics chains expanding from metros into tier 2 and tier 3 cities are the most common healthcare investment in the unlisted space. Evaluation criteria:
- Revenue per test (indicates pricing power vs. commodity labs)
- EBITDA margin (best-in-class: 25–30%)
- Hub-and-spoke model efficiency
- Home collection percentage (growing metric post-COVID)
Compare to: Dr Lal PathLabs (P/E ~35x), Metropolis Healthcare (P/E ~35–45x)
### Hospital Chains Unlisted hospital chains are typically regional players — a 2–5 hospital network in a geography. Key factors:
- Occupancy rate (above 65% is healthy for most geographies)
- ARPOB (Average Revenue Per Occupied Bed) — a key efficiency metric
- Debt level (hospital capex is high; leverage kills otherwise good operators)
- Specialty mix (oncology, cardiac, ortho command better realisations than general medicine)
Compare to: Aster DM Healthcare, Krishna Institute of Medical Sciences (KIMS), Rainbow Children's Medicare
### Digital Health Telemedicine platforms, health-tech startups, and health insurance distribution companies have raised significant venture capital. The unlisted secondary market for these is thin and illiquid — prices are often stale from the last primary round and may not reflect current fundamentals.
### Medtech and Medical Devices India's domestic medical device manufacturing remains nascent but is growing. Companies making consumables (catheters, syringes, PPE) have more predictable revenue than capital equipment makers. The government's PLI scheme for medical devices is supporting some players.
### CDMO / Pharma Manufacturing Contract development and manufacturing organisations (CDMOs) serving global pharma companies are among the most valuable sub-sectors. Key factors:
- Client concentration (a CDMO with 3 clients has high risk)
- USFDA and EU GMP compliance status (critical for export)
- Capacity utilisation and capex cycle
- Customer pipeline (late-stage molecules being manufactured are near-term revenue)
Valuation Benchmarks
| Sub-sector | Typical P/E range (listed peers) | Unlisted discount | |---|---|---| | Diagnostics | 30–45x | 30–40% discount | | Hospital chains | 25–40x | 30–40% discount | | Pharma / generic | 20–35x | 20–30% discount | | CDMO | 35–60x | 30–40% discount | | Medtech | 30–50x | 30–50% discount |
Unlisted investments should ideally enter at a meaningful discount to listed peers, given the illiquidity premium.
Key Risks
- 1Regulatory risk: CDSCO (drugs regulator), MCI, and NABH accreditation can be revoked, impacting operations
- 2USFDA risk for pharma: A USFDA warning letter can cut a company's export revenue overnight
- 3Promoter quality**: Healthcare is an operator-intensive business; bad operators burn capital quickly
- 4Insurance claim rejections: For hospitals, rising insurer rejections or TPA issues can compress realisations
*Published by the Polemarch editorial team. Not investment advice.*